Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.3k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #831

    morgan stanley der har sat deres robot til at købe nu hvor TA indikere medvind

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #832

      Link Preview Image
      Roche publicerer nye sklerosedata for at holde Novartis fra døren

      Med den nyligt godkendte sklerosemedicin Kesimpta - oprindeligt udviklet af Genmab - er Novartis i fuld gang med at lange ud efter Roches dominerende lægemiddel på markedet, og nu prøver Roche at slå igen.

      favicon

      (medwatch.dk)

      1 Reply Last reply
      0
      • Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktørH Offline
        Helge_LarsenPI-redaktør
        wrote on sidst redigeret af
        #833

        Langers Skarpe: Deltag i festen, men undgå tømmermænd og forlad den i tide

        Just a moment...

        favicon

        (www.proinvestor.com)

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #834

          Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis / Dara https://www.newswire.ca/news-releases/darzalex-r-sc-becomes-the-first-and-only-health-canada-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis-a-rare-disease-849615211.html

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #835

            CEO Jan van de Winkel rykker op på førstepladsen i Økonomisk Ugebrevs årlige CEO Performance-ranking. https://ugebrev.dk/ledelse/genmab-vinder-ceo-performance-redningsplan-blev-succes/

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #836

              waiting for this, New trial - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04847596

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #837

                yes, pretty important these days

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #838

                  These results obtained after 12 months of maintenance therapy reveal the potential of D-VRd and D-R maintenance as a new treatment for patients with NDMM who are eligible for transplant.
                  https://multiplemyelomahub.com/medical-information/daratumumab-plus-vrd-vs-vrd-in-newly-diagnosed-mm-griffin-trial-updated-analysis

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #839

                    i expect this to be an area we will hear a lot more about , Dara maintanenance, we should be getting more and more data there. Also hope we will get some smoldering data soon. Next areas of expansion.

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #840

                      Just a moment...

                      favicon

                      (www.firstwordpharma.com)

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #841

                        DARZALEX SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          peter12
                          wrote on sidst redigeret af
                          #842

                          Old news 😉 (15:12)

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #843

                            God morgen. 🙂

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #844

                              Asien: Frygt for nye nedlukninger presser japanske selskaber https://www.proinvestor.com/investornyt/674191/asien-frygt-for-nye-nedlukninger-presser-japanske-selskaber

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #845

                                Genmab/DNB: Kursmål løftet 9 pct. https://www.proinvestor.com/investornyt/674193/genmab-dnb-kursmal-loftet-9-pct-gent

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #846

                                  Tirsdagens danske avisuddrag med Danske Bank, Lego og Hummel https://www.proinvestor.com/investornyt/674194/tirsdagens-danske-avisuddrag-med-danske-bank-lego-og-hummel

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    Plimsoller
                                    wrote on sidst redigeret af
                                    #847

                                    God morgen 🙂

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #848

                                      Genmab/Deutsche Bank: Indleder med "køb" og kursmål på 2750 kr. https://www.proinvestor.com/investornyt/674199/genmab-deutsche-bank-indleder-med-kob-og-kursmal-pa-2750-kr

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #849

                                        looking back, I have 7 changes from DNB within the last 6 months since early november lol

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          kkjoel
                                          wrote on sidst redigeret af
                                          #850

                                          Yeah, noticed that as well. I guess that analyst has never heard of: "Time in the market beats timin' the market". 😉

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger